Investor Presentation

29 X Ongoing Phase 3 DETERMINE Study 52 Week study Study Commenced December 2018 Double-blind, randomized, placebo-controlled study Multinational ÎÒÅÒÂÎÄÎÎ ~150 subjects Lenabasum 20mg BID 5mg BID Placebo 2:1:2 dosing Primary Endpoint: American College of Rheumatology (ACR) / European League Against Rheumatism (EULAR) 2016 Total Improvement Score (TIS) in Adult Dermatomyositis & Polymyositis Secondary Endpoints: Change in CDASI activity score

View entire presentation